Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

86.10 +1.05 (+1.23%)
Streaming Delayed Price Updated: 11:34 AM EDT, Oct 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 1,248,866
Open 85.18
Bid (Size) 86.10 (2)
Ask (Size) 86.11 (1)
Prev. Close 85.05
Today's Range 84.80 - 86.64
52wk Range 62.07 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 3.48%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Will GILEAD SCIENCES INC breakout?
Technical Signals Point to a Possible Breakout for GILEAD SCIENCES INC. 
Via Chartmill
Gilead Sciences to Release Third Quarter 2024 Financial Results on Wednesday, November 6, 2024
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
+3.44%
+3.44%
1 Month
+3.54%
+3.54%
3 Month
+21.59%
+21.59%
6 Month
+27.08%
+27.08%
1 Year
+8.71%
+8.71%

More News

Read More
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Via Benzinga
Gilead to Present Late-Breaking Data Highlighting Antiviral Portfolio, Innovative Research Pipeline and HIV Leadership at IDWeek 2024
From Gilead Sciences, Inc.
Via Business Wire
Peeling Back The Layers: Exploring Gilead Sciences Through Analyst Insights
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $8,800 Today
Via Benzinga
Biotech Stocks Poised For Another Big Move In Q4
Via Talk Markets
Gilead Presents Additional Efficacy, Safety and Demographic Data From PURPOSE 2 Trial at 5th HIV Research for Prevention Conference
From Gilead Sciences, Inc.
Via Business Wire
S&P 500 Could Reach 6,300 In 12 Months, Says Goldman Sachs, Driven By 'Strong AI Demand' And 'Margin Expansion'
Via Benzinga
Topics Artificial Intelligence Stocks
Exposures Artificial Intelligence US Equities
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields
Via Benzinga
News Is Noise
Via Talk Markets
Gilead Sciences Unusual Options Activity For September 20
Via Benzinga
Gilead Signs Royalty-Free Voluntary Licensing Agreements With Six Generic Manufacturers to Increase Access to Lenacapavir for HIV Prevention in High-Incidence, Resource-Limited Countries
From Gilead Sciences, Inc.
Via Business Wire
Top 4 Health Care Stocks That May Keep You Up At Night
Via Benzinga
Gilead Sciences Recalls One Lot Of Its COVID-19 Treatment Due To Presence Of Glass Particles
Via Benzinga
Topics Product Recall
Exposures COVID-19 Legal Product Safety
Biotech Boom Ahead? Key Stocks and ETFs to Watch Now
Via MarketBeat
Topics ETFs Economy
Exposures Economy Interest Rates
$100 Invested In This Stock 20 Years Ago Would Be Worth $900 Today
Via Benzinga
AstraZeneca Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
Via Investor's Business Daily
3 Dirt Cheap Stocks to Buy Right Now
Via The Motley Fool
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
Via Benzinga
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Via The Motley Fool
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Why Gilead Sciences Stock Thrashed the Market Today
Via The Motley Fool
Gilead Unveils 'Remarkable Outcomes' From Late-Stage Lenacapavir Study Showing Promise In Preventing HIV Infections
Via Benzinga
Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention
Via Investor's Business Daily
Topics Intellectual Property
Exposures Intellectual Property
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.